Pfizer has issued a voluntary nationwide recall of lots of Accupril due to N-nitroso-quinapril content.
Pfizer has issued a voluntary nationwide recall of five lots of Accupril (Quinapril HCl) tablets distributed by Pfizer due to the presence of a nitrosamine, N-nitroso-quinapril, that is above the Acceptable Daily Intake (ADI) level.
Accupril is meant to lower blood pressure to treat hypertension, as well as for the management of heart failure as adjunctive therapy in addition to conventional therapy such as diuretics and/or digitalis. Pfizer is not aware of any adverse events that have been assessed to be related to this recall.
Nitrosamines are common and everyone is exposed to some level of them. However, if exposed to them above acceptable levels over long periods of time, they may increase the risk of cancer. While long-term ingestion of N-nitroso-quinapril may be associated with a potential increased cancer risk, Pfizer states that there is no immediate risk to patients taking this medication. Patients currently taking this product should consult with their health care provider about alternative treatment options.
The product lots, DR9639, DX8682, DG1188, DX6031, and CK6260, were distributed nationwide to wholesalers and distributers in the United States and Puerto Rico from December 2019 to April 2022. Pfizer has notified direct consignees by letter to arrange for return of the recalled product and urges any entities with existing inventory of the lots to cease distribution and quarantine the product immediately. The recall is being conducted with the knowledge of FDA.
Source: Pfizer
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.